Intensity Therapeutics, Inc., a privately held biotechnology company based in Westport, has announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study.

“Bringing our novel product into human testing is a major milestone,” commented President and CEO Lewis H. Bender. “Over the past few years our Company has demonstrated impressive tumor shrinkage in several murine models of cancers. INT230-6 eradicated large tumors, activated a systemic immune response and improved survival.”